Table 5.
Twenty Top Predicted Therapeutic Relationships for Hormone-refractory Prostate Cancer
rank | agent | TREATS | Active |
---|---|---|---|
1 | gefitinib | ✓ | |
2 | paclitaxel | ✓ | ✓ |
3 | gemcitabine | ✓ | ✓ |
4 | resveratrol | ✓ | |
5 | methotrexate | ✓ | |
6 | sorafenib | ✓ | |
7 | tretinoin | ✓ | |
8 | cyclophosphamide | ✓ | |
9 | cyclosporine | ✓ | |
10 | epigallocatechin gallate | ||
11 | sirolimus | ✓ | |
12 | fluorouracil | ✓ | |
13 | troglitazone | ||
14 | dactinomycin | ✓ | |
15 | estradiol | ||
16 | topotecan | ✓ | ✓ |
17 | cycloheximide | ✓ | |
18 | docetaxel | ✓ | ✓ |
19 | dehydroepiandrosterone | ||
20 | celecoxib | ✓ |